Table 3 Differentially expressed circulating miRNAs in gestational hypertension and their effects in heart disease
From: Pregnancy-associated cardiac dysfunction and the regulatory role of microRNAs
miRNA | Regulation in human pregnancy | Ref. | Heart disease | Mechanism and outcome | Ref. |
|---|---|---|---|---|---|
miR-29a | ↑ serum | [194] | Patients with hypertrophic cardiomyopathy | ↑ miR-29a → ↑ cardiac hypertrophy, ↑fibrosis | |
Mouse TAC | ↓ miR-29a → ↓ cardiac hypertrophy, ↓fibrosis | [170] | |||
ET-1 in H9c2 cardiomyocytes | ↓ NFATc4 → ↓ cardiomyocyte hypertrophy | [171] | |||
miR-125-5p | ↓ plasma | [184] | Mouse LAD ligation | ↓ bak1, ↓ klf13 → ↓ cardiomyocyte apoptosis | [139] |
miR-181a | ↑ serum | [194] | Human with AMI or unstable angina | ↑ oxidative stress marker lipid hydroperoxide | [195] |
Rat LAD ligation | ↓ TGF-β type III receptor in cardiac fibroblasts → ↑ collagen I, ↑ fibronectin | [196] | |||
Rat abdominal aortic constriction | ↓ miR-181a → ↑ ATG5 → ↑ hypertrophy | [197] |